The Manufacturers Life Insurance Company Purchases New Position in Haemonetics Corporation $HAE

Posted by on Sep 2nd, 2026

The Manufacturers Life Insurance Company acquired a new position in Haemonetics Corporation (NYSE:HAE – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 42,536 shares of the medical instruments supplier’s stock, valued at approximately $3,190,000. The Manufacturers Life Insurance Company owned approximately 0.09% of Haemonetics as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Haemonetics by 3.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier’s stock worth $1,877,000 after buying an additional 971 shares during the period. Caxton Associates LLP purchased a new position in shares of Haemonetics during the first quarter valued at $216,000. United Services Automobile Association bought a new stake in shares of Haemonetics in the first quarter valued at about $212,000. Empowered Funds LLC raised its holdings in shares of Haemonetics by 9.1% in the first quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier’s stock valued at $283,000 after acquiring an additional 372 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Haemonetics by 6.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,138 shares of the medical instruments supplier’s stock worth $9,923,000 after acquiring an additional 9,051 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Haemonetics Stock Performance

HAE stock opened at $101.97 on Wednesday. Haemonetics Corporation has a one year low of $47.31 and a one year high of $109.57. The firm has a market cap of $4.64 billion, a price-to-earnings ratio of 49.99, a PEG ratio of 2.06 and a beta of 0.54. The company has a debt-to-equity ratio of 1.40, a quick ratio of 1.91 and a current ratio of 3.08. The firm has a 50-day simple moving average of $86.08 and a two-hundred day simple moving average of $70.67.

Haemonetics (NYSE:HAE – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.08 by $0.06. Haemonetics had a net margin of 7.12% and a return on equity of 27.55%. The firm had revenue of $339.38 million for the quarter, compared to the consensus estimate of $327.86 million. During the same quarter in the previous year, the firm earned $1.10 EPS. The company’s quarterly revenue was up 5.5% compared to the same quarter last year. On average, equities analysts forecast that Haemonetics Corporation will post 5.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

HAE has been the topic of a number of research reports. Mizuho raised their target price on shares of Haemonetics from $85.00 to $90.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. JPMorgan Chase & Co. upped their price target on shares of Haemonetics from $62.00 to $86.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. Robert W. Baird lifted their price objective on shares of Haemonetics from $96.00 to $119.00 and gave the company an “outperform” rating in a report on Friday, August 21st. Citigroup boosted their price objective on shares of Haemonetics from $79.00 to $92.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. Finally, Raymond James Financial restated an “outperform” rating and set a $105.00 target price on shares of Haemonetics in a report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Haemonetics currently has an average rating of “Moderate Buy” and a consensus target price of $97.56.

Read Our Latest Stock Analysis on HAE

Haemonetics Company Profile

(Free Report)

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.

Read More

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.